Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Canopy Growth (CGC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal second quarter.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.
What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.
Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?
by Zacks Equity Research
Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.
Universal Health (UHS) to Report Q3 Results: What to Expect
by Zacks Equity Research
Universal Health's (UHS) third-quarter earnings results are likely to reflect depressed revenues and weak admissions.
Centene's (CNC) Q3 Earnings Improve Y/Y on High Revenues
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect higher revenues and managed care membership.
Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) third-quarter earnings results are likely to reflect elevated costs and a softness in Commercial business line.
Tenet Healthcare's (THC) Earnings Beat in Q3, Improve Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.
Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands
by Zacks Equity Research
Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands
Is it Finally Time to Buy Marijuana Stocks?
by Tracey Ryniec
With new states set to legalize cannabis this November, and the possibility of federal legalization looming, will the marijuana stocks finally live up to the hype?
Canopy Growth (CGC) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's How to Play a Likely Biden Win
by Sanghamitra Saha
Per an ABC News/Washington Post national poll released on Oct 11, Biden has a lead over Trump by 12 percentage points nationally.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $14.20, marking a -0.84% move from the previous day.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $14.17, moving -0.7% from the previous trading session.
Canopy Growth Corporation (CGC) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $16.36, moving -0.24% from the previous trading session.
Implied Volatility Surging for Canopy Growth (CGC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Company News for Aug 11, 2020
by Zacks Equity Research
Companies In The News Are: CGC, GOLD, RCL, MAR.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 28.57% and 16.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $19.21 in the latest trading session, marking a -0.57% move from the prior day.
Analysts Estimate Canopy Growth Corporation (CGC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $18.60, moving +0.59% from the previous trading session.